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Background—Sudden death (SD) is a frequent catastrophic complication in patients after myocardial infarction.
Circumstances of SD may affect strategies for prevention.
Methods and Results—We reviewed source documentation for 1067 patients who had SD in the Valsartan in Acute
Myocardial Infarction Trial (VALIANT) trial. We determined the circumstances of these events and assessed long-term
mortality in patients who were resuscitated. Location of the SD event was available in 978 of 1067 patients, with 226
events occurring within the first 40 days. Although SD was more likely to occur at home (645 of 978, 66%) than in
hospital (204 of 978, 21%), the proportion of in-hospital events was higher early on (99 of 226, 44%). Home events were
less likely to be witnessed regardless of time frame. Preceding activity was known for 42% of patients with home arrest;
of these, 52% were determined to be asleep at time of event, and these deaths were more likely to be unwitnessed. A
majority of patients for whom initial ECG rhythm was reported had ventricular tachycardia/ventricular fibrillation (189
of 283, 67%). Of the 155 patients successfully resuscitated, 24% subsequently received an implantable cardioverter-
defibrillator. Nineteen percent of those who received an implantable cardioverter-defibrillator subsequently died
compared with 49% of patients who did not receive an implantable cardioverter-defibrillator (hazard ratio, 0.36; 95%
confidence interval, 0.14 to 0.93; P0.04).
Conclusions—A high proportion of SD events after high-risk myocardial infarction occurred at home, but in-hospital
events were more common early on. Patients who were asleep were more likely to have unwitnessed arrests. Alternative
strategies for the prevention of SD in patients who are not candidates for implantable cardioverter-defibrillator will need
to take into account the circumstances of SD events. (Circulation. 2011;123:2674-2680.)
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The risk of sudden unexpected death is elevated insurvivors of acute myocardial infarction (MI).1–4 Al-
though primary prevention with implantable cardioverter-
defibrillators (ICDs) is of known benefit in a select subset of
high-risk patients with reduced left ventricular ejection frac-
tion, strategies for preventing sudden death in those who are
not eligible for ICD therapy remain elusive.5–7 In particular,
both the Defibrillator in Acute Myocardial Infarction Trial
(DINAMIT) and the Immediate Risk-Stratification Improves
Survival (IRIS) trial failed to demonstrate any mortality
benefit for early ICD implantation in post-MI patients with
decreased ejection fraction,8,9 despite the substantial burden
of sudden death events in this population.3 In part to address
this therapeutic lack, the Home Automated External Defibril-
lator Trial (HAT) investigated the use of home automated
external defibrillators (AEDs) in patients with history of
anterior MI who were otherwise not candidates for ICD.10
Despite a small number of patients who were successfully
resuscitated with home AEDs, the trial failed to demonstrate
significant improvement in overall survival. A high propor-
tion of unwitnessed home arrests may have contributed to the
lack of a statistical benefit because AEDs require bystanders
to be present to operate the device and to achieve successful
defibrillation.7,11
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Although the circumstances of out-of-hospital cardiac ar-
rest in the general population have been well described, there
has been only limited characterization of the context of
sudden death events in patients with prior MI.12–16 To better
understand the circumstances and outcomes of sudden death
events over time in high-risk patients after MI, we studied
patients with sudden unexpected death or cardiac arrest with
resuscitation in the Valsartan in Acute Myocardial Infarction
Trial (VALIANT).
Methods
The double-blind, randomized, controlled VALIANT assessed treat-
ment with valsartan, captopril, or both in 14 703 patients with acute
MI complicated by heart failure, left ventricular systolic dysfunction,
or both.17 Patients were enrolled at 931 hospitals in 24 countries
between December 1998 and June 2001. For this analysis, 94
patients who received an ICD before randomization were excluded.
A detailed description of the population and protocol, including
inclusion and exclusion criteria, has been published previously.12
A central, blinded adjudication committee reviewed all deaths and
episodes of cardiac arrest with resuscitation using source documen-
tation provided by individual sites. Sudden death was explicitly
defined as death that occurred suddenly and unexpectedly in a patient
who was otherwise clinically stable, with no documentation of heart
failure, MI, or another clear cause of death; except for rare cases,
deaths during the index hospitalization were not adjudicated as
sudden death. Sudden death events were further adjudicated by the
central committee into 3 categories: witnessed, not witnessed, but
with the patient seen within 1 hour of death, and not witnessed, with
the patient seen 1 hour but 24 hours before death. Patients who
were last seen 24 hours before death were not considered to have
had sudden death. The time course of sudden cardiac death in
VALIANT has been previously described.3 Cardiac arrest with
resuscitation was defined as cardiac arrest from which the patient
regained consciousness and subsequent cognitive function, even if
briefly. For the purposes of this analysis, cardiac arrests with
resuscitation were categorized as witnessed events.
Source documentation for all episodes of sudden unexpected
deaths or cardiac arrest with resuscitation was reviewed when
available. A standardized abstraction instrument was used to capture
data elements pertaining to circumstances of the arrest event,
including location of event, preceding symptoms, preceding activity,
and initial ECG rhythm, if known. Location was classified as at
home, in hospital (including emergency room), or at other public
settings. The presence of preceding symptoms was defined as
symptoms within 24 hours of the event that could be retrospectively
interpreted as being of cardiac origin, including chest discomfort,
dyspnea, syncope, or other.18 For preceding activity, each patient
was classified as being asleep at the time of sudden death if there was
witnessed account of patient sleeping, or, for arrests that were not
witnessed, if the patient was found recumbent in bed. Initial ECG
rhythm was defined as the initial rhythm documented after the arrest
had taken place. For patients who were classified as being awake,
whether the patient was physically active or at rest at the time of
event was also recorded. In addition, we described in detail the above
measures for patients who experienced sudden death events within
first 40 days and first 90 days of their index MI.
For patients who experienced cardiac arrest with resuscitation, we
identified those who received ICD implantation within 42 days of the
event and those who did not. All comparisons of baseline clinical
characteristics were performed with the Student t test for continuous
variables and the 2 test for categorical variables. To account for
potential survivor bias, we performed a landmark analysis using
Kaplan–Meier methods by excluding patients who died or were
censored within 42 days of their initial event. Hazard ratios were
derived through the use of step-wise Cox proportional hazards
regression with a cutoff of P0.05 for all baseline covariates that
had value of P0.20 in the initial univariate analysis, as per Maldonado
and Greenland.19 Assumption of proportional hazards for each covari-
ates and globally was confirmed with a formal significance test based on
Schoenfeld residuals. All statistical analysis was performed with
STATA version 10.0 (Stata Corp, College Station, TX).
Results
Of 14 609 patients enrolled in VALIANT who were eligible
for analysis, 1067 (7%) had sudden death or cardiac arrest,
including 903 patients who died and 164 patients who were
resuscitated after cardiac arrest. In total, 1486 patients died of
nonsudden cardiovascular causes and 385 patients of noncar-
diovascular causes. Compared with surviving patients with-
out events, patients who had sudden unexpected death or
cardiac arrest with resuscitation were significantly older; had
higher baseline systolic and diastolic blood pressures and
high baseline heart rate; had higher Killip class and lower left
ventricular ejection fraction; had higher rates of diabetes
mellitus, hypertension, and prior MI; were less likely to have
been treated with percutaneous coronary intervention or
thrombolytic therapy; and were less likely to have been
receiving -blockers or amiodarone (Table 1). As our group
has reported previously,3 baseline characteristics between
patients who died of other causes, both cardiovascular and
noncardiovascular, and patients who had sudden unexpected
death or cardiac arrest resuscitation, were much more similar.
Source documentation was available for 1062 of 1067 pa-
tients who had sudden death or cardiac arrest. Of these, 251
patients had an event within the first 40 days of their index MI,
140 patients had an event 41 to 90 days after their index MI, and
671 patients had an event 90 days after their index MI. The
presence or absence of preceding symptoms was documented
for 710 of 1062 patients (Table 2). A majority of patients did
not have any preceding symptoms (385 of 710, 54%). Of the
325 patients (46%) for whom preceding symptoms were
reported, shortness of breath (165 of 325, 51%) and chest pain
(161 of 325, 50%) were the most common. Initial ECG
rhythm was reported for 283 of 1062 patients (Table 2), of
which two thirds were ventricular fibrillation or ventricular
tachycardia (189 of 283, 67%), followed by asystole (59 of
283, 21%) and pulseless electric activity (17 of 283, 6%).
Compared with the entire cohort, patients who had events
within the first 40 days of their index MI had essentially
identical preceding symptoms and initial ECG rhythms (Ta-
ble 2), as did patients who had events within the other
specified time periods.
The location at which sudden unexpected death or cardiac
arrest resuscitation occurred was documented for 978 of 1062
patients. Roughly two thirds of sudden death events happened
at home (645 of 978, 66%) compared with approximately one
fifth of events that occurred in hospital (204 of 978, 21%); the
remainder of events took place in settings that were outside
the home, but not in hospital (129 of 978, 13%). However, the
proportion of events that occurred in hospital was higher for
patients who had sudden death within the first 40 days (99 of
226, 44%) of their index MI, which then diminished over
time. Only a small proportion of events occurring 90 days
after index MI took place in hospital (83 of 623, 13%).
Regardless of the time frame, only about half of the sudden
death events that occurred at home were witnessed compared
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with the much higher proportion of witnessed events that
occurred in hospital and in other public settings (Table 2).
We assessed preceding activity for the 645 patients who
had sudden unexpected death or cardiac arrest with resusci-
tation at home. Preceding activity was known for 269 of 645
patients (42%; Table 3). Of these, half were determined to
have been asleep at the time of event (139 of 269, 52%), and
the remainder were determined to have been awake (130 of
269, 48%). The patients who were determined to be asleep at
the time of arrest were far less likely to have witnessed events
(27 of 139, 19%) compared with those who were determined
to be awake (91 of 130; 70%). For patients who were
determined to be awake, a third were reported to have been
physically active at the time of the event (48 of 130, 37%),
whereas half were reported to have been at rest (65 of 130;
50%). A similar proportion of patients with sudden death
events who were determined to be asleep versus awake was
observed during all time periods, with similar rates of
witnessed events (Table 3).
Outcomes of Resuscitated Patients
Of the 1067 patients who had sudden death or cardiac arrest,
164 were successfully resuscitated. Compared with those in
whom resuscitation was not successful, patients who were
resuscitated were more likely to have had an event in hospital,
to have been randomized in the United States, and to have
been treated with thrombolytic therapy or percutaneous cor-
onary intervention during their index MI. Other clinical and
demographic covariates were not significantly different be-
tween the 2 groups. Of the 164 patients who had cardiac
arrest with resuscitation, 4 had ICD implantation before the
event. Another 5 patients died on the same day despite initial
successful resuscitation. Of the 155 remaining patients, 37
(24%) subsequently received ICD implantation within 42
days of the sudden death event. The median time between
sudden death event and ICD implantation was 11 days.
Compared with the 118 patients who had cardiac arrest with
resuscitation but did not undergo ICD implantation, those
who received an ICD were significantly more likely to be
male, to have higher peak creatine kinase at the time of the
index MI, to have undergone primary percutaneous coronary
intervention at the time of the index MI, and to have been
randomized in the United States (Table 4). Other covariates,
including age, body mass index, estimated glomerular filtra-
tion rate, history of MI or heart failure, time from index MI
to cardiac arrest with resuscitation, and proportion of cardiac
Table 1. Baseline Characteristics of Patients According to Study Outcome
Characteristic
Sudden Unexpected
Death or Cardiac
Arrest With Resuscitation
(n1067)
Death Resulting
From Nonsudden
Cardiovascular
Causes (n1486)
Death Resulting From
Noncardiovascular
Causes (n385)
Survival Free of Sudden
Death or Cardiac Arrest
With Resuscitation
(n11 671)
Age, y 67.811.2 71.210.3* 71.710.3* 63.511.7*
Male, % 67 60* 66 70*
Blood pressure, mm Hg
Systolic 125.118.2 123.317.3* 123.917.8 122.316.7*
Diastolic 73.312.0 72.111.9* 71.511.8* 72.311.1*
Heart rate, bpm 78.113.6 79.713.9* 76.713.0 75.612.5*
Body mass index, kg/m2 27.75.7 27.35.0* 26.55.2* 28.05.3*
Killip class, %
I 20 16* 22 30*
II 46 46 49 49
III 26 28 21 15
IV 9 11 8 5
Clinical or radiographic
evidence of CHF, %
83 86* 82 75*
Prior MI, % 45 42 37* 24*
Diabetes mellitus, % 31 33 27 21*
Hypertension, % 64 65 59 53*
-blocker, % 61 56* 64 73*
Amiodarone, % 4 5 5 8*
Primary PCI, % 8 8 9 17*
Thrombolytic therapy, % 24 25 26 38*
Primary PCI or thrombolytic
therapy, %
30 31 34 50*
LVEF, % 32.110.0 32.610.2 34.110.5* 36.010.3*
CHF indicates heart congestive heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; and LVEF, left
ventricular ejection fraction. Values are meanSD when appropriate. Percentages may not sum to 100 because of rounding.
*Denotes P0.05 vs sudden unexpected death or cardiac arrest with resuscitation.
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arrest with resuscitation occurring within 40 days of index
MI, were similar between the 2 groups. The mean and median
durations of follow-up were 474.9 and 451 days, respectively.
Of the 37 patients who received an ICD, 7 (19%) subse-
quently died during the follow-up period compared with 58 of
118 patients (49%) who did not receive an ICD. To account
for potential survivor bias, we excluded all patients who died
or were censored within 42 days of their initial event from
further analysis, including 25 who did not receive an ICD and
3 who did. We then applied stepwise variable selection using
Table 2. Details of Sudden Death Events
Total
(n1062), n (%)
Within 40 Days
of Index MI
(n251), n (%)
41 to 90 Days
After Index MI
(n140), n (%)
90 Days After
Index MI
(n671), n (%)
Symptoms
Preceding symptoms present* 325 (31) 80 (32) 36 (26) 209 (31)
Shortness of breath 165/325 (51) 42/80 (52) 16/36 (44) 107/209 (51)
Chest pain 161/325 (50) 44/80 (55) 17/36 (47) 100/209 (48)
Syncope 35/325 (11) 9/80 (11) 4/36 (11) 22/209 (11)
Other 76/325 (23) 14/80 (18) 6/36 (17) 56/209 (27)
No preceding symptoms 385 (36) 85 (34) 52 (37) 248 (37)
Unknown symptoms 352 (33) 86 (34) 52 (37) 214 (32)
Initial ECG rhythms
Initial rhythm recorded 283 (27) 114 (45) 33 (24) 136 (20)
VF/VT 189/283 (67) 80/114 (70) 22/33 (67) 87/136 (64)
Asystole 59/283 (21) 22/114 (19) 7/33 (21) 30/136 (22)
PEA 17/283 (6) 5/114 (4) 3/33 (9) 9/136 (7)
Other 18/283 (6) 7/114 (6) 1/33 (3) 10/136 (7)
Unknown rhythm 779 (73) 137 (55) 107 (76) 535 (80)
Location of arrest
Location known 978 (92) 226 (90) 129 (92) 623 (93)
Home 645/978 (66) 117/226 (52) 96/129 (74) 432/623 (69)
Witnessed 320/645 (50) 62/117 (53) 52/96 (54) 206/432 (48)
Unwitnessed 325/645 (50) 55/117 (47) 44/96 (46) 226/432 (52)
Hospital 204/978 (21) 99/226 (44) 22/129 (17) 83/623 (13)
Witnessed 179/204 (88) 90/99 (91) 19/22 (86) 70/83 (84)
Unwitnessed 25/204 (12) 9/99 (9) 3/22 (14) 13/83 (16)
Other public setting 129/978 (13) 10/226 (4) 11/129 (9) 108/623 (17)
Witnessed 97/129 (75) 9/10 (90) 6/11 (55) 82/108 (76)
Unwitnessed 32/129 (25) 1/10 (10) 5/11 (45) 26/108 (24)
Location unknown 84 (8) 25 (10) 11 (8) 48 (7)
VF indicates ventricular fibrillation; VT, ventricular tachycardia; and PEA, pulseless electric activity. Percentages may not add up
to 100% because of rounding.
*More than 1 preceding symptoms may be reported for each patient.
Table 3. Preceding Activity and Witness Status for Patients Who Had Sudden Unexpected Death or
Cardiac Arrest With Resuscitation at Home*
Sudden Death
at Home, Total
(n645), n (%)
Within 40 Days
of Index MI
(n117), n (%)
41 to 90 Days
After Index MI
(n96), n (%)
90 Days After
Index MI
(n432), n (%)
Preceding activity known 269 (42) 40 (34) 39 (41) 190 (44)
Determined to be awake 130/269 (48) 18/40 (45) 17/39 (44) 95/190 (50)
Witnessed event 91/130 (70) 15/18 (83) 12/17 (71) 64/95 (67)
Last seen within 1 h of discovery 23/130 (18) 1/18 (6) 3/17 (18) 19/95 (20)
Last seen 1 h before discovery 16/130 (12) 2/18 (11) 2/17 (12) 12/95 (13)
Determined to be asleep 139/269 (52) 22/40 (55) 22/39 (56) 95/190 (50)
Witnessed event 27/139 (19) 3/22 (14) 6/22 (27) 18/95 (19)
Last seen within 1 h of discovery 17/139 (12) 0/22 (0) 4/22 (18) 13/95 (14)
Last seen 1 h before discovery 95/139 (69) 19/22 (86) 12/22 (55) 64/95 (67)
Preceding activity unknown 376 (58) 77 (66) 57 (59) 242 (56)
MI indicates myocardial infarction. Percentages may not add up to 100% because of rounding.
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all covariates with a value of P0.20 in the univariate
analysis, including age at time of index MI, sex, peak creatine
kinase, primary percutaneous coronary intervention, and ran-
domization in the United States. The only covariates that
remained in the model and were significant were ICD
placement (hazard ratio, 0.36; 95% confidence interval, 0.14
to 0.93; P0.04; the Figure) and age (hazard ratio, 1.04 for
each year of increasing age; 95% confidence interval, 1.01 to
1.07; P0.01). The hazard ratio for ICD placement was
similar to that in the unadjusted model (hazard ratio, 0.35;
95% confidence interval 0.13 to 0.89; P0.03). The assump-
tions of proportional hazards for both models were confirmed
for each covariate and globally with a formal significance test
based on Schoenfeld residuals. Finally, restricting the analy-
sis to those who had cardiac arrest with resuscitation within
first 40 days of the index MI changed the hazard ratio
slightly, but the P value was no longer significant (hazard
ratio, 0.44; 95% confidence interval, 0.10 to 2.01; P0.29).
Discussion
In this retrospective analysis of patients enrolled in VALIANT, we
described the circumstances and outcomes of sudden unex-
pected death and cardiac arrest with resuscitation in survivors
of acute MI with left ventricular dysfunction, heart failure, or
both. We showed that sudden death events were often
heralded by preceding symptoms, and the initial ECG
rhythms were often ventricular tachycardia or ventricular
fibrillation. Overall, the most frequent location for sudden
death events was home, although early after MI, a higher
proportion of events occurred in hospital. Regardless of the
time frame, events at home were less likely to be witnessed,
especially if the onset was during sleep. For patients who had
cardiac arrest with resuscitation, those who subsequently
received ICD implantation appeared to have a much more
favorable outcome.
Our findings were generally consistent with those from
HAT and other trials regarding the circumstances of out-of-
hospital cardiac arrest. The proportion of sudden death events
that occurred at home in VALIANT was similar to that reported
in HAT, whereas the proportion of events that occurred in
hospital was slightly higher, likely reflecting the increased
burden of symptomatic heart failure in the VALIANT popula-
tion.7,10–13 Initial ECG rhythm was ventricular tachycardia or
ventricular fibrillation for the majority of patients who had
recorded rhythm in our study, which lies on the higher end of
the range reported in patients with out-of-hospital cardiac
arrest.9,11,20 These differences are likely due to different
prevalences of ischemic heart disease and heart failure in the
populations studied, as well as the selection bias that stems
from the difficulty of fully characterizing all arrest events
when many of them are not witnessed. Regardless, our results
reinforce the facts that a high proportion of sudden death
events in patients with prior MI occur at home, and that a
substantial proportion of those events are preceded by symp-
toms and manifest initially as ventricular tachycardia or
ventricular fibrillation.
Despite a high proportion of shockable rhythms associated
with sudden death events at home, the availability of home
AED in HAT was not associated with any benefit in overall
survival. Our observation that a large proportion of at-home
Table 4. Baseline Characteristics of Patients With Cardiac
Arrest With Resuscitation by Subsequent Implantation of a
Cardioverter-Defibrillator
Characteristics
Cardiac
Arrest With
Resuscitation
Without ICD
Cardiac
Arrest With
Resuscitation
With ICD P
Patients, n 118 37
Age at time of index MI, y 67.510.3 65.19.8 0.20
Male sex, n (%) 79 (67) 31 (84) 0.049
Systolic blood pressure,
mm Hg
120 (110–130) 118 (110–130) 0.57
Body mass index, kg/m2 27.75.5 29.04.7 0.21
eGFR, mL  min1  1.73
m2
64.722.0 67.520.5 0.49
LVEF, % 31.18.0 31.18.8 0.98
Previous MI, n (%) 54 (46) 14 (38) 0.40
Previous heart failure,
n (%)
28 (24) 8 (22) 0.79
Diabetes mellitus, n (%) 30 (25) 13 (35) 0.25
Peak CK at time of index
MI, U/L
856 (466–2237) 1994 (577–3466) 0.011
Primary PCI at time of
index MI, n (%)
40 (34) 23 (62) 0.0003
Time from index MI to
cardiac arrest with
resuscitation, d
158.921.4 205.850.2 0.33
Cardiac arrest with
resuscitation within first
40 d of index MI, n (%)
59 (50) 16 (43) 0.47
Randomized in United
States, n (%)
20 (17) 24 (65) 0.0001
ICD indicates implantable cardioverter-defibrillator; MI, myocardial infarc-
tion; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection
fraction; CK, creatine kinase; and PCI, percutaneous coronary intervention.
Figure. Kaplan–Meier survival curves for patients with and with-
out an implantable cardioverter-defibrillator (ICD) implantation
after cardiac arrest with resuscitation. *In the final step-wise
Cox proportional hazards regression analysis, only age and ICD
placement remained significant and were included in the model.
HR indicates hazard ratio.
2678 Circulation June 14, 2011
sudden death events occur during sleep, and are thus unwit-
nessed, may shed light on this negative result. In our analysis,
only 19% of patients who were determined to be asleep had
witnessed events, compared with 70% of those who were
awake. We were able to determine sleep status for fewer than
half of the patients who had an event at home. Because we
used a strict criterion of classifying patients as being sleeping
only if they were witnessed or if they were found recumbent
in bed, the observed relationship between circadian activities
and witness status is likely true and generalizable. Given the
known association between whether an event is witnessed
and the outcome of resuscitation, our findings are also
consistent with other studies that showed decreased survival
during nighttime for patients with out-of-hospital cardiac
arrest, especially in residential settings.21,22 It is thus not
surprising that bystander-dependent and location-restricted
strategies of sudden death prevention, such as home AED,
turned out to be ineffective. Future efforts for the prevention
of sudden death in patients with MI who are not eligible for
ICD therapy will require better risk stratification, including
an improved understanding of how risk factors evolve over
time.23 Proposed interventions will need to demonstrate that
their application can be consistent during high-risk time
periods such as sleep, as has been suggested in the most
recent registry of wearable cardioverter defibrillators.24 For
the subset of high-risk patients with reduced ejection fraction
immediately after MI who are not eligible for ICD implan-
tation, preventive strategies will also have to take into
account the high proportion of early events that occur in
hospital and are thus not amenable for home interventions,
such as AED or a wearable cardioverter defibrillator.
Our analysis also showed significantly improved survival
for patients who received an ICD after cardiac arrest with
resuscitation, although the decision to implant an ICD was
clinically based and subject to several important biases, the
most significant being geographic location. A substantially
higher proportion of patients who received an ICD were
randomized in the United States, and differences in healthcare
settings and processes of care may remain potential con-
founders despite statistical adjustment. In addition, given that
this was a retrospective analysis based on a small, nonran-
domized cohort, the decision to offer ICD therapy may be
considerably influenced by other risk features that we failed
to capture, and we may not be able to completely eliminate
the potential survivor bias in the decision for ICD implant-
ation despite statistical adjustment. Despite these limitations,
taken together, our findings are consistent with previous trials
that established the use of ICDs for secondary prevention of
sudden death and can be considered illustrative of the
efficacy for the use of this strategy in a real-world setting.25–28
As with all post hoc analyses, our findings were necessarily
hypothesis generating. Despite the availability of source
documentation for nearly all sudden death events, the level of
detail regarding the circumstances of the events varied greatly
by center and by geographic region, and individual data
elements such as preceding activity and initial ECG rhythm
were missing for a substantial number of patients, introducing
potentially significant bias. In addition, although we used a
standardized abstraction instrument, the primary descriptions
of the data elements of interest did not follow any standard-
ized criteria such as those commonly used to categorize
out-of-hospital cardiac arrests.29 Finally, despite adjudication
performed by a blinded, central committee, misclassification
of other causes of death (eg, reinfarction, myocardial rupture,
or noncardiac) as sudden death is likely unavoidable, as has
been suggested by recent reviews of autopsy series, including
those from the VALIANT cohort.30,31 Because the adjudica-
tion criteria excluded patients with immediate antecedent MI
or heart failure as having sudden death, we may also have
missed the many deaths from arrhythmia that occur in those
settings.
Conclusions
Our data show that most sudden death events in patients with
high-risk MI occurred at home, were often preceded by
symptoms, and had ventricular tachycardia or ventricular
fibrillation as the initial ECG rhythm. Location of event and
sleep were shown to be strongly associated with whether an
arrest was witnessed. The risk of death for patients who did
not receive ICD therapy after cardiac arrest with resuscitation
remained dramatically elevated. These findings have impli-
cation for future strategies to prevent sudden death in patients
with MI who are otherwise not candidates for ICD.
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CLINICAL PERSPECTIVE
Sudden unexpected death is a frequent catastrophic complication in patients after myocardial infarction. For patients such
as those with reduced ejection fraction immediately after myocardial infarction who are not eligible for implantable
cardioverter-defibrillator therapy, strategies for prevention have remained elusive. In this study, we explored the
circumstances of sudden death events in patients with high-risk myocardial infarction. We showed that only half of sudden
death events occurring at home were witnessed, in part because of a high proportion (50%) of events occurring during
sleep. We also demonstrated that early after myocardial infarction there was an increased likelihood of sudden death events
occurring in hospital (44% within the first 40 days versus 21% for the entire follow-up period). Taken together, these
findings help to explain the lack of efficacy of home automatic external defibrillators and suggest that strategies for
prevention in this patient population should take into account the circumstances of sudden death events. Finally, we
assessed the outcomes of patients who were successfully resuscitated after cardiac arrest, illustrating the benefit of
secondary prevention implantable cardioverter-defibrillator therapy (hazard ratio for death 0.36; P0.04).
2680 Circulation June 14, 2011
